Sildenafil (Generic) and Progesterone HRT Interaction

Who Takes Both of These Medications?

The combination of sildenafil and progesterone HRT arises in several clinical scenarios that prescribers should recognize. While sildenafil is FDA-approved for erectile dysfunction and pulmonary arterial hypertension (PAH), progesterone HRT is prescribed to menopausal and perimenopausal women as part of combined hormone therapy [1][2].

Female Patients on HRT with Pulmonary Hypertension

Sildenafil (marketed as Revatio at 20 mg three times daily) is a first-line treatment for WHO Group 1 PAH. Women receiving menopausal HRT who develop PAH, or who already carry a PAH diagnosis, may need both drugs simultaneously. The SUPER-1 trial (N=278) demonstrated that sildenafil 20 mg TID improved 6-minute walk distance by 45 meters versus placebo in PAH patients [3].

Off-Label Use in Female Sexual Dysfunction

A growing body of literature examines sildenafil for female sexual arousal disorder. A randomized trial by Caruso et al. (N=98) found that sildenafil 50 mg improved arousal scores in postmenopausal women already receiving estrogen-progesterone HRT [4]. These patients take both drugs by design.

Transgender Women on Feminizing HRT

Transgender women receiving progesterone as part of feminizing hormone regimens may also use sildenafil for erectile function preservation. The Endocrine Society's 2017 clinical practice guideline acknowledges the use of progesterone in some feminizing protocols, though evidence remains limited [5].

Pharmacokinetic Interaction: CYP3A4 Overlap

Both sildenafil and progesterone are metabolized by cytochrome P450 3A4, which raises the question of whether co-administration alters drug levels. The short answer: the effect is clinically minor for most patients.

Sildenafil Metabolism

Sildenafil undergoes extensive first-pass hepatic metabolism. CYP3A4 is the principal enzyme, with CYP2C9 contributing as a secondary pathway [1]. Peak plasma concentration occurs at 30-120 minutes, and the terminal half-life is approximately 3-5 hours. The FDA label explicitly warns that strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase sildenafil AUC by 182-312%, requiring dose reduction [1].

Progesterone Metabolism

Oral micronized progesterone (Prometrium) is also a CYP3A4 substrate, metabolized to multiple hydroxylated compounds and further reduced to allopregnanolone, the neuroactive metabolite responsible for sedation [2]. Progesterone's plasma half-life after oral dosing is 16-18 hours in the sustained phase.

Why the Interaction Stays Minor

Progesterone is not a potent CYP3A4 inhibitor or inducer. Unlike ketoconazole (which increases sildenafil exposure nearly 3-fold), progesterone at standard HRT doses (100-200 mg nightly) does not produce meaningful enzyme inhibition [6]. No published pharmacokinetic study has demonstrated a clinically significant rise in sildenafil AUC when co-administered with oral progesterone. The theoretical competition for CYP3A4 binding is diluted by the enzyme's high hepatic abundance and the relatively low doses of both drugs in this context.

Patients taking additional CYP3A4 inhibitors (clarithromycin, grapefruit juice, certain HIV protease inhibitors) alongside both drugs should be monitored more closely, as the additive enzyme load could tip the balance toward elevated sildenafil levels [1].

Pharmacodynamic Interaction: Sedation and Dizziness

The more relevant concern is not metabolic but pharmacodynamic. Both drugs independently produce central nervous system effects that can overlap.

Progesterone and GABA-A Receptor Activity

Oral micronized progesterone generates allopregnanolone, a potent positive allosteric modulator of the GABA-A receptor [7]. This is the same receptor complex targeted by benzodiazepines and barbiturates. The Prometrium label reports drowsiness in 54% of patients receiving 300 mg daily and 48% at 200 mg daily, versus 22% with placebo [2]. Dizziness occurs in 24% at the 300 mg dose.

Dr. JoAnn Pinkerton, former executive director of the North American Menopause Society, has noted: "Oral progesterone's sedative effect is well-established and is actually considered a benefit for women with menopausal sleep disruption, but clinicians must account for it when adding other medications that cause dizziness" [8].

Sildenafil and Vasodilation-Related Dizziness

Sildenafil inhibits phosphodiesterase type 5 (PDE5), producing vasodilation through the nitric oxide-cGMP pathway. This vasodilation lowers systemic blood pressure by a mean of 8.4/5.5 mmHg (systolic/diastolic) at the 100 mg dose [1]. Dizziness is reported in 2% of patients at 25-50 mg and 4% at 100 mg in clinical trials.

Combined Effect

When a patient takes both drugs, the sedation from progesterone's GABAergic metabolite adds to sildenafil's vasodilation-induced lightheadedness. This is not a synergistic pharmacologic interaction in the classical sense. It is additive symptom overlap. The patient who takes oral progesterone at dinner and sildenafil 30 minutes later is more likely to experience drowsiness, dizziness, or unsteadiness than with either drug alone.

No large-scale study has quantified the exact incidence of combined sedation. The risk is highest in the first 1-3 hours after oral progesterone dosing, when allopregnanolone levels peak [7].

Blood Pressure Considerations

Sildenafil's Hemodynamic Profile

Sildenafil produces a modest, predictable blood pressure reduction. In healthy volunteers, 100 mg caused a mean maximum decrease of 8.4 mmHg systolic and 5.5 mmHg diastolic [1]. The nadir occurs 1-2 hours post-dose and resolves within 4-6 hours. The FDA label warns against use with nitrates (absolute contraindication) and alpha-blockers (relative caution) because of additive hypotension.

Progesterone's Blood Pressure Effects

Progesterone is generally considered blood pressure-neutral or mildly vasodilatory. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) found no significant difference in systolic blood pressure between women receiving oral micronized progesterone 200 mg cyclically and those on placebo over 4 years [9]. Some mechanistic data suggest progesterone antagonizes aldosterone at the mineralocorticoid receptor, producing a mild natriuretic effect [10].

Clinical Relevance

The additive hypotensive potential of this combination is small. Patients with baseline systolic blood pressure above 110 mmHg are unlikely to experience symptomatic drops. Patients who are already on antihypertensives (particularly alpha-blockers or diuretics) warrant closer monitoring. Standing blood pressure should be checked at the first visit after initiating the combination.

Dose Timing and Practical Management

Separating the two medications by time of day is the simplest risk-reduction strategy. This approach does not require dose changes to either drug.

Recommended Timing Protocol

The Prometrium label recommends bedtime dosing specifically because of the sedation profile [2]. Sildenafil for erectile dysfunction is taken as needed, typically 30-60 minutes before sexual activity. For PAH (20 mg TID), the last dose of the day should be taken at least 2 hours before progesterone.

A practical schedule for a menopausal woman on both drugs:

• Progesterone 200 mg at bedtime (e.g., 10:00 PM)
• Sildenafil as needed, ideally taken in the afternoon or early evening, at least 2-4 hours before the progesterone dose
• If sildenafil is used for PAH at 20 mg TID, schedule doses at 7 AM, 1 PM, and 6 PM, with progesterone at 10 PM

When to Start Low

For patients initiating sildenafil while already established on progesterone HRT, starting at 25 mg allows assessment of tolerability before titrating to 50 mg or 100 mg. The 2023 American Urological Association guideline on erectile dysfunction supports starting at the lowest effective dose in patients with polypharmacy [11].

Monitoring Recommendations

Baseline Assessment

Before co-prescribing, clinicians should document:

• Resting blood pressure (seated and standing)
• Current medication list, with attention to other CYP3A4 substrates or inhibitors
• History of syncope, orthostatic hypotension, or falls
• Progesterone dose and timing

Ongoing Monitoring

The 2022 North American Menopause Society position statement on hormone therapy recommends annual reassessment of HRT regimens, including review of concomitant medications [12]. For patients on both sildenafil and progesterone, add the following to routine visits:

• Ask about dizziness, drowsiness, or lightheadedness after taking both drugs
• Check seated and standing blood pressure if symptoms are reported
• Review adherence to dose-separation timing

Red Flags Requiring Immediate Evaluation

Sustained systolic blood pressure below 90 mmHg, syncope, or prolonged drowsiness exceeding 4 hours after either dose should prompt urgent reassessment. These events are rare at standard doses but more likely in patients who are elderly, have hepatic impairment (which slows clearance of both drugs), or are taking additional CNS depressants [1][2].

Special Populations

Hepatic Impairment

Both sildenafil and progesterone are hepatically cleared. The sildenafil FDA label recommends a starting dose of 25 mg in patients with hepatic impairment, as AUC increases by 47% in mild-to-moderate cirrhosis [1]. The Prometrium label notes that progesterone metabolites accumulate in liver disease, potentially intensifying sedation [2]. Co-administration in patients with Child-Pugh B or C cirrhosis requires individualized dosing and heightened monitoring.

Older Adults

Women over 65 show higher progesterone plasma levels due to decreased hepatic clearance [2]. Sildenafil clearance is also reduced by approximately 40% in adults over 65, leading to 90% higher AUC compared with younger adults [1]. The combination in this age group warrants starting sildenafil at 25 mg and monitoring for orthostasis.

Renal Impairment

Sildenafil AUC increases by 100% in severe renal impairment (creatinine clearance <30 mL/min), and a 25 mg starting dose is recommended [1]. Progesterone pharmacokinetics are not significantly altered by renal function, as excretion is primarily biliary [2].

What the Drug Labels Actually Say

Neither the sildenafil nor the progesterone FDA-approved label lists the other drug as a specific interaction concern. The sildenafil label warns broadly about CYP3A4 inhibitors and nitrates [1]. The Prometrium label warns about "drowsiness and dizziness" and advises against activities requiring alertness after dosing, but does not name PDE5 inhibitors [2].

The 2017 Endocrine Society guideline on testosterone therapy in men (which addresses concomitant PDE5 inhibitor use) does not discuss progesterone co-administration [5]. Similarly, the 2022 NAMS hormone therapy position statement does not address PDE5 inhibitor interactions [12].

This absence of specific warnings reflects the low clinical severity of the interaction. It does not mean the interaction is zero. It means it has not risen to the level of a labeled contraindication or precaution.

Patient Counseling Points

Prescribers should communicate the following to patients receiving both medications:

• Take progesterone at bedtime to align its sedative peak with sleep
• If using sildenafil as needed, allow at least 2 hours between doses
• Do not drive or operate heavy machinery after taking both drugs within the same 2-hour window
• Avoid alcohol on days when both medications are taken, as alcohol compounds both vasodilation and sedation
• Report dizziness, fainting, or excessive drowsiness at the next visit
• Grapefruit juice inhibits CYP3A4 and can increase sildenafil levels; limit intake [1]

The 2023 AUA/SMSNA guideline on ED management states: "Patient education regarding potential additive effects of concomitant medications should be part of every PDE5 inhibitor prescription encounter" [11].

Patients using sildenafil 20 mg TID for PAH should coordinate dose timing with their pulmonologist and gynecologist to avoid scheduling overlap with bedtime progesterone.